JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page.Highlights

Transplantation of iPSC-derived neural precursor cells (NPCs) shows beneficial effects for spinal cord injury (SCI).

Because unsafe iPSC-NPC lines can form tumors after grafting, provisions to attenuate this risk are substantially important.

Clinical application for SCI patients using iPSCs will be conducted in the near future.

For the past few decades, spinal cord injury (SCI) has been believed to be an incurable traumatic condition, but with recent developments in stem cell biology, the field of regenerative medicine has gained hopeful momentum in the development of a treatment for this challenging pathology. Among the treatment candidates, transplantation of neural precursor cells has gained remarkable attention as a reasonable therapeutic intervention to replace the damaged central nervous system cells and promote functional recovery. Here, we highlight transplantation therapy techniques using induced pluripotent stem cells to treat SCI and review the recent research giving consideration to future clinical applications.

Spinal cord injury

Neural precursor cells

Induced pluripotent stem cells

Clinical application

neural precursor cells

induced pluripotent stem cells

high mobility group box-1

swine leukocyte antigen

mixed lymphocyte reaction

human leukocyte antigen

peripheral blood mononuclear cells

directly reprogrammed neural precursor cells

-secretase inhibitor

herpes simplex virus type I thymidine kinase

oligodendrocyte progenitor cells

the Center for iPS Cell Research and Application

American Spinal Injury Association

chondroitin sulfate proteoglycans

Recommended articlesCiting articles (0)

2019 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.

Here is the original post:
Cell therapy for spinal cord injury using induced ...